Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Depression and anxiety with rimonabant.

Literature DB >> 18022023

Depression and anxiety with rimonabant.

Philip B Mitchell¹, Margaret J Morris.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2007 PMID： 18022023 DOI： 10.1016/S0140-6736(07)61705-X

Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321

Keyword Cloud
Cited

× No keyword cloud information.

22 in total

Review 1. Adenosine-cannabinoid receptor interactions. Implications for striatal function.

Authors: Sergi Ferré; Carme Lluís; Zuzana Justinova; César Quiroz; Marco Orru; Gemma Navarro; Enric I Canela; Rafael Franco; Steven R Goldberg
Journal: Br J Pharmacol Date: 2010-06 Impact factor: 8.739

Review 2. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.

Authors: Cyrus DeSouza; Vivian Fonseca
Journal: Nat Rev Drug Discov Date: 2009-05 Impact factor: 84.694

Review 3. From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders.

Authors: Jane B Acri; Alan J Cross; Phil Skolnick
Journal: Psychopharmacology (Berl) Date: 2016-12-20 Impact factor: 4.530

Review 4. Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors: Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal: Neuropsychopharmacology Date: 2015-06-12 Impact factor: 7.853

Review 5. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.

Authors: Gitanjali Srivastava; Caroline Apovian
Journal: Curr Obes Rep Date: 2018-06

6. Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report.

Authors: Mateus M Bergamaschi; Regina H C Queiroz; Marcos H N Chagas; Ila M P Linares; Kátia C Arrais; Danielle C G de Oliveira; Maria E Queiroz; Antonio E Nardi; Marilyn A Huestis; Jaime E C Hallak; Antonio W Zuardi; Fabrício A Moreira; José A S Crippa
Journal: Hum Psychopharmacol Date: 2013-12-03 Impact factor: 1.672

Depression and anxiety with rimonabant.

Review 1. Adenosine-cannabinoid receptor interactions. Implications for striatal function.

Review 2. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.

Review 3. From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders.

Review 4. Neurobiological Interactions Between Stress and the Endocannabinoid System.

Review 5. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.

6. Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report.

Review 7. New drugs for type 2 diabetes mellitus: what is their place in therapy?

8. Receptor heteromerization and drug discovery.

9. What is the best treatment for prediabetes?

10. Pharmacotherapies for obesity: past, current, and future therapies.